Highlights of This Issue  4907

SPECIAL FEATURES

The Tissue Is the Issue:
Personalized Medicine for Non-Small Cell Lung Cancer
Fred R. Hirsch, Murry W. Wynes, David R. Gandara, and Paul A. Bunn, Jr.
See article p. 4938

Comparing Survival Curves Using an Easy to Interpret Statistic
Kenneth R. Hess

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Andrew C. Hsieh and Davide Ruggero

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Robert Justice, and Richard Pazdur

Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Charlotte E. Edling, Federico Selvaggi, Richard Buus, Tania Maffucci, Pierluigi Di Sebastian, Helmut Friess, Paolo Innocenti, Hemant M. Kocher, and Marco Falasca

EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Yuichi Sakairi, Takahiro Nakajima, Kazuhiro Yasufuku, Dai Ikebe, Hajime Kageyama, Manabu Soda, Kengo Takeuchi, Makiko Itami, Toshihiko Iizasa, Ichiro Yoshino, Hiroyuki Mano, and Hideki Kimura

Statistics in Clinical Cancer Research

4912 Comparing Survival Curves Using an Easy to Interpret Statistic
Kenneth R. Hess

Molecular Pathways

4914 Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Andrew C. Hsieh and Davide Ruggero

Report from the FDA

4921 Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Robert Justice, and Richard Pazdur

CANCER THERAPY: PRECLINICAL

Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Kevin O. Hicks, Bronwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijn, Annie M. Fraser, Rita Patel, Alison Hogg, H.D. Sarah Liyanage, Mary Jo Doria, J. Martin Brown, William A. Denny, Michael P. Hay, and William R. Wilson

Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
Roberta Irapollii, Elena Tamborini, Emanuela Virdis, Ezia Bello, Eva Tarantino, Sergio Marchini, Federica Grosso, Roberta Sanfilippo, Alessandro Gronchi, Juan Carlos Tercero, Gabriella Pelosi, Paolo Casali, Silvana Pilotti, and Maurizio D’Incalci

Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer
Ghazal Hariri, Heping Yan, Hailun Wang, Zhaozhong Han, and Dennis E. Hallahan

A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes
Marcia D. Jones, Julie C. Liu, Thomas K. Barthel, Sadiq Hussain, Erik Lovria, Dengfeng Cheng, Jesse A. Schoonmaker, Sudhanshu Mulay, David C. Ayers, Mary L. Bouzsein, Gary S. Stein, Siddhartha Mukherjee, and Jane B. Lian
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Erika Martinelli, Teresa Troiani, Floriana Morgillo, Gabriella Rodolico, Donata Vitagliano, Maria Pia Morelli, Concetta Tuccillo, Loredana Vecchione, Anna Capasso, Michele Orditura, Ferdinando De Vita, S. Gail Eckhardt, Massimo Santoro, Liberato Berrino, and Fortunato Ciardiello

Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin

Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
Tetsuya Hamaguchi, Toshihiko Doi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Nozomu Fuse, Atsushi Ohtsu, Shin-ichi Matsumoto, Masaya Takanashi, and Yasuhiro Matsumura

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, Ajay Nooka, Amelia A. Langston, Leonard T. Heffner, Claire Torre, Stephanie McMillan, Heather Renfroe, R. Donald Harvey, Mary J. Lechowicz, H. Jean Khoury, Christopher R. Flowers, and Edmund K. Waller

Correction: Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue
Chang-Qi Zhu, Dan Strumf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica
ABOUT THE COVER

A humanized, monoclonal antibody against PDGFRα was able to inhibit both early colonization of the bone and late progression of skeletal lesions in a murine model of prostate cancer metastasis. The image shows a metastatic tumor produced in the proximal femur by green fluorescent PC3-ML cells, four weeks after being inoculated via the hematogenous route. For further details, please see the article by Russell and colleagues on page 5002 of this issue.